ATE194753T1 - Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist - Google Patents

Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist

Info

Publication number
ATE194753T1
ATE194753T1 AT92907704T AT92907704T ATE194753T1 AT E194753 T1 ATE194753 T1 AT E194753T1 AT 92907704 T AT92907704 T AT 92907704T AT 92907704 T AT92907704 T AT 92907704T AT E194753 T1 ATE194753 T1 AT E194753T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
movement disorder
opiator
modulating
hyperkinetic movement
Prior art date
Application number
AT92907704T
Other languages
English (en)
Inventor
Conan Kornetsky
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Application granted granted Critical
Publication of ATE194753T1 publication Critical patent/ATE194753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT92907704T 1991-02-25 1992-02-25 Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist ATE194753T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66054391A 1991-02-25 1991-02-25
PCT/US1992/001418 WO1992014364A1 (en) 1991-02-25 1992-02-25 Opiate receptor antagonist modulates hyperkinetic movement disorder

Publications (1)

Publication Number Publication Date
ATE194753T1 true ATE194753T1 (de) 2000-08-15

Family

ID=24649948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907704T ATE194753T1 (de) 1991-02-25 1992-02-25 Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist

Country Status (9)

Country Link
US (1) US6153620A (de)
EP (1) EP0573565B1 (de)
JP (1) JPH06505747A (de)
AT (1) ATE194753T1 (de)
AU (1) AU658401B2 (de)
CA (1) CA2104229C (de)
DE (1) DE69231274T2 (de)
ES (1) ES2148174T3 (de)
WO (1) WO1992014364A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
PL2368553T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
ES2540551T3 (es) 2007-03-29 2015-07-10 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8796301B2 (en) 2007-04-24 2014-08-05 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
GB2543271A (en) * 2015-10-12 2017-04-19 Lars Holger Hermann Dr Products for treating psychogenic pain disorders

Also Published As

Publication number Publication date
EP0573565B1 (de) 2000-07-19
AU1456392A (en) 1992-09-15
DE69231274T2 (de) 2000-11-30
AU658401B2 (en) 1995-04-13
EP0573565A1 (de) 1993-12-15
JPH06505747A (ja) 1994-06-30
ES2148174T3 (es) 2000-10-16
WO1992014364A1 (en) 1992-09-03
CA2104229C (en) 1997-04-15
DE69231274D1 (de) 2000-08-24
EP0573565A4 (de) 1994-03-18
US6153620A (en) 2000-11-28
CA2104229A1 (en) 1992-08-26

Similar Documents

Publication Publication Date Title
ATE194753T1 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
DK0817847T4 (da) IL-17-receptor
ATE360032T1 (de) Cystein-reiche rezeptoren-train
DZ1763A1 (fr) Composition vaccinantes.
GB9319695D0 (en) Substituted-2-phenyl-3-methoxypropenoates as fungicides
BG101194A (en) New heteroaryl oxazolidinons
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
AU2793992A (en) Tricyclic quinoxalinediones as glutamate receptor antagonists
EP0714295A4 (de)
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
DE69201906T2 (de) Zylinderbüchse.
ATE227122T1 (de) Stabilisierte tablettenformulierung
DE69202890D1 (de) Zylinderlaufbüchse.
EP0344979A3 (de) Alpha-adrenergische Rezeptorantagonisten
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
HU9400417D0 (en) New leukotriene-b4 antagonists, methods for producing them and their use as drugs
TW343973B (en) Morphinan derivative and medical use
GR1001394B (el) Παράγωγα 4-[4-[4-(4-υδροξυφαινυλ)-1-πιπεραζινυλ] φαινυλ]-5-με?υλ3Η-1,2,4-τριαζολ-3-όνης.
ITMI910284U1 (it) Portamanifesto, particolarmente utile per un'installazione all'aperto
ITRM930635A0 (it) Composizione per biscotti aventi proprieta' antiacide.
ITTO940212V0 (it) Attrezzatura per compassi sostitutiva dell'ago.
LT2367B (lt) seka 5'-ggpypu cc-3',gavimo budas endonukleazes-restriktazes, skeliancios nukleotidu

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee